书签 分享 收藏 举报 版权申诉 / 69

类型智慧芽:2022中美口服新冠药对比&全球3CL抑制剂专利分析报告(69页).pdf

  • 上传人:小**
  • 文档编号:88987
  • 上传时间:2022-08-05
  • 格式:PDF
  • 页数:69
  • 大小:4.24MB
  • 配套讲稿:

    如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。

    特殊限制:

    部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。

    关 键  词:
    智慧 2022 中美 口服 新冠药 对比 全球 CL 抑制剂 专利 分析 报告 69
    资源描述:

    《智慧芽:2022中美口服新冠药对比&全球3CL抑制剂专利分析报告(69页).pdf》由会员分享,可在线阅读,更多相关《智慧芽:2022中美口服新冠药对比&全球3CL抑制剂专利分析报告(69页).pdf(69页珍藏版)》请在三个皮匠报告文库上搜索。

    1、!#$%&()*+,-*(./0+1.*23(4(546.2780!?!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$!#$%&()*!%&()!%!%#*+,-&./01!%!#!+*,-./012345*6!#%*+23456&7!%!$!#%#*+23489:;!6*,78-7/09:;123$&*=!$%!*?56ABCD89)!%!E!$%#!+?56ABCD89*?;!S*6AB!#CDETUVW*!X!G%HIJKLM$NO!#PQRST!%!U!G%VW$NO!#PQR!

    2、%!E!G%#XVW$NO!#PQR!%!#!G%#YZ$NO!#PQRIJ!%!$F!G%#%2_Sa$NO!#PQRabcIJ!%!$F!#$%&()*+,-.!#$#/01()*+,-$!G%#%#d_SaIJ)!%!$#!#$2345,-#!#67289:;!#-67289?ABC9DE=(),-F!#G 67289HIJKLMNDE OPOQ,-R!#!,STUVWX,YZXZWWX,-R!#F,T_T,STUaTWb_ZTcX,-d!#R,eZfT,YZXZWWX,G.!#d,gbXZW,YZhTUaT,G.!#$.,iUjX_Tc,STUaT,G$!#$,eklmng,oWUTh

    3、Wb_ZX,G#!#$#,pki,STUaT,G-!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!#$%&!#$#?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!$%&(!)*+,#?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$!$#!()*+,-./01!$!%&-./01!2#?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$%&-./345678#?!#$%&()*+,-*(./0+1.*23(4(

    4、546.2780!?!G!?!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!U!#$%&()*+,-*(./0+1.*23(4(546.2780!?!E!%#!(23)2+,%4567-./$!?%!#%901:;347$#?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!f!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!F!?%$#&901:;347$#?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!&#!8967%(!#:;?A!?!#$%&()*+,-*(./0+1.*23(4(54

    5、6.2780!?!#!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e!?)#!BCDE%(!#/F89GH!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!U!*#!%(!#:;FGF#FF$#FFe#FF#FFG#FFU#FFE#FFf#FF#F#F#F$#Fe#F#FG#FU#FE#Ff#F#F#F#F#!#

    6、$%&()*+,-.FF#F$FeFFGFUFEFfFFF*?+?g?h?i?j?klmnL/012#$%&()*34!#$%&()*+,-*(./0+1.*23(4(546.2780!?!E!#!$%&!#$%?XVWo!Efo!GEpVWo!e#o!$#p567856#$%9:;&()*e#FF#F#$F+?*?h?j?56#$%9:;&()*134?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!f!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#F!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!?!#$

    7、%&()*+,-*(./0+1.*23(4(546.2780!?!#!#(&!$%&!#$%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#$!?!#?$%&?()*?+,?-.?/01?234?5?6789?:3*?;91?234?ABCD?(E?FG4H?IJK.?!#?$%&?()*?+,?-.?/01?234?5?6789?:3*?;?ABCD?!#?$?%&?(?)*+?&,-#?./0?12?34?567?8094?:6;(?LMNAOPAQRS?ST?FG4H?IJK.?!#?$%&?()*?+,?-.?/01?234?ABCD?U?*?V?WX?Y3

    8、?Z?X*?D_%?.?a?!#?$%&?6789*?:3?b?LMNAOPAQRS?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#e!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#U!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#E!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#f!?!#$%&()*+,-*(./0+1

    9、.*23(4(546.2780!?!$F!&$JKLM%(!#EFGANO#!(#()*+$%&!#$%*+,-./0?!#$!#$%&%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$!?!#$#()*#$%&%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$#!?!(1()*+23/045!#$+,-.%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$e!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$

    10、!?!#/0+123456#$%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$U!?!#&/0+12789:2;?ABC;56#$%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$E!?!#)DEDF%?!#!%*+,-./%012/31.43./%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$f!#5%64+47+%*8+,9+3.:713+;/%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!eF!

    11、#+%012/31.43./%?!#?%:4/814.%012A8+,9+%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e!?!#$B%C23,D/7+;%*8+,9+%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e#!?!#$%=EFGH%I8.,+A.:713/%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e$!#$#%JEC%*8+,9+%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!ee!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e!?!

    12、#$%&()*+,-*(./0+1.*23(4(546.2780!?!eG!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!eU!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!eE!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!ef!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!F!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!?!#$%&()*+,-*(./0+1.*23(4(5

    13、46.2780!?!$!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!U!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!E!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!f!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!GF!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G#!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G$!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!Ge!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!GG!?https:/!

    展开阅读全文
    提示  三个皮匠报告文库所有资源均是用户自行上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作他用。
    关于本文
    本文标题:智慧芽:2022中美口服新冠药对比&全球3CL抑制剂专利分析报告(69页).pdf
    链接地址:https://www.sgpjbg.com/baogao/88987.html
    关于我们 - 网站声明 - 网站地图 - 资源地图 - 友情链接 - 联系我们 - 行业研究网

    copyright@ 2008-2013        长沙景略智创信息技术有限公司版权所有
    网站备案/许可证号:湘ICP备17000430号-2